Where world-class pediatric medicine meets heartfelt compassion — dedicated to the health and happiness of children from around the world.
State-of-the-Art Facility
Beijing, China
Beijing Jingdu Children's Hospital is a 40,000 square meter, JCI-accredited tertiary children's hospital located in Beijing, China. As one of the country's premier pediatric medical institutions, we combine cutting-edge medical technology with compassionate, family-centered care.
We are renowned as Asia's #1 Pediatric Stem Cell Transplant Center, performing over 900 hematopoietic stem cell transplants annually. Our hospital has served families from over 100 countries, offering world-class pediatric treatment at significantly lower costs than comparable Western institutions.
We aspire to be a beacon of excellence and innovation in children's medicine — setting global standards for pediatric care and illuminating the path to healing for children everywhere.
Every child deserves the best possible medical care, delivered with warmth and compassion. We dedicate ourselves to healing children with advanced medicine and nurturing families with genuine kindness.
Beijing Jingdu Children's Hospital is proud to hold Joint Commission International (JCI) accreditation, the gold standard in global healthcare quality. JCI accreditation means our hospital meets the most rigorous international standards for patient safety, clinical quality, and healthcare management — the same standards applied to the world's top hospitals.
For international families, JCI accreditation provides confidence that your child will receive care that meets or exceeds the standards of leading hospitals in your home country.
Led by internationally recognized pediatric specialists with decades of experience and groundbreaking research achievements.
A pioneering figure in pediatric hematology with decades of clinical and research experience. Under his leadership, Jingdu Children's has become Asia's largest pediatric HSCT center, performing over 900 transplants annually with industry-leading survival rates.
A distinguished hematologist recognized with China's State Council Special Contribution honor. Her groundbreaking work on modified haploidentical transplantation pretreatment for primary HLH achieved a 2-year survival rate of 78.4% and a 5-year rate of 73.7%.
An internationally acclaimed pediatric cardiac surgeon and pioneer in right lateral minithoracotomy for congenital heart diseases. Has led over 2,000 successful cardiac surgeries, making complex heart procedures accessible and minimally invasive for children.
State-of-the-art infrastructure designed specifically for pediatric care and international family comfort.
Our advanced central laboratory enables precision diagnosis through cutting-edge gene sequencing, molecular testing, and comprehensive pathology services. This facility supports our innovative treatments including CAR-T cell therapy, CIK/NK cell therapy, and targeted gene therapies for rare pediatric diseases.
The laboratory's research capabilities directly translate into improved clinical outcomes, enabling personalized treatment approaches for complex conditions including leukemia, genetic disorders, and rare diseases.
Our dedicated international inpatient department features 16 modern family wards designed for the comfort of both children and their parents during extended treatment stays.
Each ward includes: